PTEN loss in intraductal carcinoma of the prostate has low incidence in Japanese patients.
ERG
IDC-P
PTEN
ethnicity
prostate cancer
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
07
2023
accepted:
02
08
2023
medline:
20
11
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Clinical and genomic features of prostate cancer (PCa) vary considerably between Asian and Western populations. PTEN loss is the most frequent abnormality in intraductal carcinoma of the prostate (IDC-P) in Western populations. However, its prevalence and significance in Asian populations have not yet been well studied. In the present study, we evaluated PTEN expression in IDC-P in a Japanese population and its association with ERG expression. This study included 45 and 59 patients with PCa with and without IDC-P, respectively, who underwent radical prostatectomy. PTEN loss was observed in 10 patients with PCa with IDC-P (22%) and nine patients with PCa without IDC-P (17%). ERG expression was relatively frequent in patients with PCa with PTEN loss, although a significant difference was not observed. The co-occurrence of PTEN loss and ERG expression was observed in four patients with PCa with IDC-P and one without IDC-P. PTEN loss and ERG expression did not affect progression-free survival, regardless of the presence of IDC-P. The frequency of PTEN loss in IDC-P is lower in Asian patients than in Western patients. Our results indicate that mechanisms underlying IDC-P in Asian populations are different from those of Western populations.
Substances chimiques
PTEN protein, human
EC 3.1.3.67
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
542-548Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21K06933
Organisme : Japan Society for the Promotion of Science
ID : 21K15392
Informations de copyright
© 2023 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Cree IA. WHO classification of tumours: urinary and male genital tumours. IARC; 2021.
Johansson JE. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA: J Am Med Assoc. 1997;277:467-471.
McNeal JE, Yemoto CEM. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20:802-814.
Downes MR, Xu B, van der Kwast TH. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. Eur J Cancer. 2021;148:432-439.
Kato M, Tsuzuki T, Kimura K, Hirakawa A, Kinoshita F, Sassa N, et al. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol. 2016;29:166-173.
Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 2014;74:680-687.
Torabi-Nezhad S, Malekmakan L, Mashayekhi M, Daneshian A. Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63. Prostate. 2016;76:394-401.
Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26:587-603.
Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol. 2015;39:169-178.
Hickman RA, Yu H, Li J, Kong M, Shah RB, Zhou M, et al. Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol. 2017;41:550-556.
Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate. 2019;79:1267-1273.
Shah RB, Yoon J, Liu G, Tian W. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology. 2017;71:693-702.
Downes MR, Satturwar S, Trudel D, van der Kwast TH. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas. Pathol Res Pract. 2017;213:34-38.
Spieker AJ, Gordetsky JB, Maris AS, Dehan LM, Denney JE, Arnold Egloff SA, et al. PTEN expression and morphological patterns in prostatic adenocarcinoma. Histopathology. 2021;79:1061-1071.
Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry C, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011-1025.
Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78-83.
Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580:93-99.
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18:282-301.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-458.
Namiki M, Akaza H, Lee SE, Song JM, Umbas R, Zhou L, et al. Prostate Cancer Working Group report. Jpn J Clin Oncol. 2010;40(Suppl 1):i70-i75.
Fukagai T, Shimada M, Yoshida H, Namiki T, Carlile RG. Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan. Int J Androl. 2000;23(Suppl 2):43-44.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genet. 2010;42:668-675.
King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genet. 2009;41:524-526.
Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol. 2014;32:206-211.
Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Hum Pathol. 2016;55:117-125.
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genet. 2009;41:619-624.
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222-234.
Fan L, Fei X, Zhu Y, Pan J, Sha J, Chi C, et al. Comparative analysis of genomic alterations across castration sensitive and castration resistant prostate cancer via circulating tumor DNA sequencing. J Urol. 2021;205:461-469.
Varma M, Delahunt B, Egevad L, Samaratunga H, Kristiansen G. Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Arch. 2019;474:525-534.
Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2016;238:31-41.
Osiecki R, Kozikowski M, Sarecka-Hujar B, Pyzlak M, Dobruch J. Prostate cancer morphologies: cribriform pattern and intraductal carcinoma relations to adverse pathological and clinical outcomes-systematic review and meta-analysis. Cancers. 2023;15:1372.
Peng YC, Tsuzuki T, Kong MX, Li J, Deng FM, Melamed J, et al. Incidence of intraductal carcinoma, multifocality and bilateral significant disease in radical prostatectomy specimens from Japan and United States. Pathol Int. 2016;66:672-677.
Pantazopoulos H, Diop MK, Grosset AA, Rouleau-Gagné F, Al-Saleh A, Boblea T, et al. Intraductal carcinoma of the prostate as a cause of prostate cancer metastasis: a molecular portrait. Cancers. 2022;14:820.
Nie L, Pan X, Zhang M, Yin X, Gong J, Chen X, et al. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center. Prostate. 2019;79:819-825.
Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, et al. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Mod Pathol. 2016;29:1565-1574.
Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. 2012;118:4053-4062.